PHARMACEUTICAL COMPOSITION COMPRISING K-RAS-SPECIFIC ACTIVATED T CELLS FOR PREVENTION AND TREATMENT OF BREAST CANCER AND METHOD FOR PREPARING SAME
A pharmaceutical composition comprising K-ras-specific activated T cells for prevention and treatment of breast cancer according to the present invention is an antigen composition wherein K-ras mutant (G12D, G12V, and G13D) recombinant overlapping peptides are sequentially divided into a total of 12 epitopes (n=1 to 12, with the proviso that the last epitope (n=12) is 23 amino acids) of 30 amino acids in an amino acid sequence of K-ras, and is designed so that sequences of 15 amino acids overlap between the epitopes. Thus, the pharmaceutical composition has the advantage of being more effective in recognizing and killing breast cancer in which the K-ras, the K-ras mutant G12V, the K-ras mutant G12D, or the K-ras mutant G13D is detected. Therefore, when the pharmaceutical composition comprising K-ras-specific activated T cells for prevention and treatment of breast cancer according to the present invention is used, there are advantages of effectively preventing and treating breast cancer, specifically, breast adenocarcinoma, in which K-ras as well as K-ras mutants are detected..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 06. Juli Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LEE WANG JUN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-07-06, Last update posted on www.tib.eu: 2023-08-08, Last updated: 2023-08-11 |
|---|
| Patentnummer: |
WO2023128379 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA01765694X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA01765694X | ||
| 003 | DE-627 | ||
| 005 | 20230811085338.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230721s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA01765694X | ||
| 035 | |a (EPA)WO2023128379 | ||
| 035 | |a (EPA)86999548 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LEE WANG JUN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PHARMACEUTICAL COMPOSITION COMPRISING K-RAS-SPECIFIC ACTIVATED T CELLS FOR PREVENTION AND TREATMENT OF BREAST CANCER AND METHOD FOR PREPARING SAME |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-07-06, Last update posted on www.tib.eu: 2023-08-08, Last updated: 2023-08-11 | ||
| 520 | |a A pharmaceutical composition comprising K-ras-specific activated T cells for prevention and treatment of breast cancer according to the present invention is an antigen composition wherein K-ras mutant (G12D, G12V, and G13D) recombinant overlapping peptides are sequentially divided into a total of 12 epitopes (n=1 to 12, with the proviso that the last epitope (n=12) is 23 amino acids) of 30 amino acids in an amino acid sequence of K-ras, and is designed so that sequences of 15 amino acids overlap between the epitopes. Thus, the pharmaceutical composition has the advantage of being more effective in recognizing and killing breast cancer in which the K-ras, the K-ras mutant G12V, the K-ras mutant G12D, or the K-ras mutant G13D is detected. Therefore, when the pharmaceutical composition comprising K-ras-specific activated T cells for prevention and treatment of breast cancer according to the present invention is used, there are advantages of effectively preventing and treating breast cancer, specifically, breast adenocarcinoma, in which K-ras as well as K-ras mutants are detected. | ||
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a bio | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a MOON HYOUN JONG |4 aut | |
| 700 | 0 | |a LIM SUN KI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 06. Juli |
| 773 | 1 | 8 | |g year:2023 |g day:06 |g month:07 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/86999548/publication/WO2023128379A1?q=WO2023128379 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 06 |c 07 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 06 |c 07 | ||